Lenalidomide, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia
Status:
Completed
Trial end date:
2014-01-01
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects and best dose of lenalidomide when given together
with cytarabine and idarubicin in treating patients with acute myeloid leukemia. Biological
therapies, such as lenalidomide, may stimulate the immune system in different ways and stop
cancer cells from growing. Drugs used in chemotherapy, such as cytarabine and idarubicin,
work in different ways to stop the growth of cancer cells, either by killing the cells or by
stopping them from dividing. Giving lenalidomide together with cytarabine and idarubicin may
kill more cancer cells.